^
    Back
    Association details:
    Biomarker:BCR-ABL1 T315I
    Cancer:Chronic Myeloid Leukemia
    Drug:Inlyta (axitinib) (VEGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Nature
    Title:

    Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

    Excerpt:
    Treatment of a T315I chronic myeloid leukaemia patient with axitinib resulted in a rapid reduction of T315I-positive cells from bone marrow.
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cell Commun Signal
    Title:

    Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

    Excerpt:
    Using different CML cell lines and models, we identified the clinically approved TKIs sorafenib (SF) and axitinib (AX) as drugs overcoming the resistance mediated by the Bcr Abl(T315I) mutant as well as the one mediated by Gab2 and Lyn(Y508F).
    DOI:
    10.1186/s12964-016-0129-y
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    J Hematol Oncol
    Title:

    Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation

    Excerpt:
    Axitinib potently inhibited the growth of T315I-mutant primary cells in a dose-dependent manner (Fig. 1g).
    DOI:
    10.1186/s13045-015-0190-9